Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

frankyz669 (22.59) Submitted: 9/3/2010 10:23:24 AM : Start Price: $2.92 SNTA Score: +105.22

Magic Formula - though speculative. I think it made the MF list because of huge cash infusion from selling its position with another partner.

smith972 (85.96) Submitted: 4/21/2010 5:30:50 PM : Start Price: $4.04 SNTA Score: +46.31

I'll watch SNTA in caps here.

cibient (< 20) Submitted: 2/4/2010 1:14:38 PM : Start Price: $4.08 SNTA Score: +28.17

Surge of insider buying inspires confidence. While this means nothing if the drug ultimately doesn't fly, or heavy dilution tramples existing shareholders, the company has a good balance sheet due to the recent capital raise.

aulden1954 (< 20) Submitted: 1/15/2010 7:51:08 PM : Start Price: $4.84 SNTA Score: +8.03

Their product base has started rough with the cancer drug but, they have good products in the pipe line that is giving some positive light on the companies pipe line of products.

I like my chances because the company has many other products they are bringing to market. If they only bring one to market and get bough out they have become a success haven't they.

iddqkfyou (< 20) Submitted: 1/13/2010 7:37:20 AM : Start Price: $4.63 SNTA Score: +15.48

Insiders just (Jan.) purchased 5+% of the company at this price. Insiders do not buy millions of their own biotech company without good reason.

dgu004 (89.10) Submitted: 12/22/2009 5:00:32 AM : Start Price: $6.50 SNTA Score: +34.24

Went too high before the trail is successful. Red ink will show again for the quarters to come.

TuffPicks (< 20) Submitted: 9/22/2009 12:17:50 PM : Start Price: $3.15 SNTA Score: +82.47

wallstreet buy list

ChicagoBreeze (< 20) Submitted: 10/23/2008 3:41:04 PM : Start Price: $5.72 SNTA Score: -58.70

Promising risky microcap biotech for various types of cancer with phase 3 interium results later out this year. One person described this as possiblly the "next celgene". Also has high insider ownership. NO insiders have sold since it went public nearly 2 years ago.

biovestor (< 20) Submitted: 6/28/2008 6:22:16 AM : Start Price: $5.93 SNTA Score: -8.17

A cancer biotech stock with a promising Phase 3 candidate for metastatic melanoma (elesclomol) along with a full early stage pipeline.

glfraley (99.08) Submitted: 1/29/2008 3:14:44 PM : Start Price: $7.15 SNTA Score: -22.86

Just won orphan status for their already fast tracked melanoma drug. should be interesting to see how this develops.

ivhadit (< 20) Submitted: 1/19/2008 6:41:50 PM : Start Price: $6.50 SNTA Score: -21.38

IF THIS HITS WATCH OUT

Dtrifan (68.60) Submitted: 11/13/2007 9:49:01 PM : Start Price: $8.37 SNTA Score: -27.60

Cancer drug market at a low price

jcarcopo (25.76) Submitted: 10/19/2007 9:55:47 AM : Start Price: $8.11 SNTA Score: -22.02

Promising Melanoma (#1 Cancer Killer) Cancer Drug. $80M upfront from Glaxo, up to $1 Billion total for milestones. Fast R&D pipeline with several other drug canidates. Plenty of insider action at $9-$10. Stage 2 trial went well, stage 3 proceeding, FDA fast track drug candidate. $12-$14 easy within a month.

myersfield (< 20) Submitted: 10/11/2007 4:05:37 PM : Start Price: $9.01 SNTA Score: -29.27

Very promising data, 400% survival benefit in mal. melanoma w/o prior chemo as in current phase 3 trial.

tharlow (80.09) Submitted: 10/11/2007 12:12:31 AM : Start Price: $9.75 SNTA Score: -34.53

Ready to explode on GSK deal. An easy double from these discounted levels.

agard43 (< 20) Submitted: 7/2/2007 12:20:09 AM : Start Price: $8.36 SNTA Score: -26.76

Highest Rated Russell 2000 stock and Insider Buying = Buy